Affimed N.V. (AFMD)
1.05
-0.07 (-6.25%)
At close: Jan 14, 2025, 3:59 PM
1.10
4.27%
Pre-market Jan 15, 2025, 05:15 AM EST
undefined% (undefined)
| Bid | 1.1 |
| Market Cap | 16.07M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.66 |
| PE Ratio (ttm) | -0.23 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.14 |
| Volume | 242,024 |
| Avg. Volume (20D) | 304,386 |
| Open | 1.16 |
| Previous Close | 1.12 |
| Day's Range | 1.05 - 1.16 |
| 52-Week Range | 1.05 - 8.95 |
| Beta | undefined |
About AFMD
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 12, 2014
Employees 76
Stock Exchange NASDAQ
Ticker Symbol AFMD
Website https://www.affimed.com
Analyst Forecast
According to 5 analyst ratings, the average rating for AFMD stock is "Buy." The 12-month stock price forecast is $12.5, which is an increase of 1084.83% from the latest price.
Buy 80.00%
Hold 20.00%
Sell 0.00%
Next Earnings Release
Affimed N.V. is scheduled to release its earnings on Mar 27, 2025,
before market opens.
Analysts project revenue of $2.23M, reflecting a 401.63% YoY growth and earnings per share of -0.8, making a -46.67% decrease YoY.
Analysts project revenue of $2.23M, reflecting a 401.63% YoY growth and earnings per share of -0.8, making a -46.67% decrease YoY.
4 weeks ago ·
Source
-29.11%
Affimed shares are trading lower. The company repo...
Unlock content with
Pro Subscription
7 months ago ·
Source
+68.51%
Affimed shares are trading higher after the company announced longer follow-up data from the EGFRwt cohort and initial clinical efficacy data from the EGFRmut cohort from the on-going AFM24-102 study in NSCLC.
